Page 17 - Read Online

Valcárcel-Nazco et al. Rare Dis Orphan Drugs J 2023;2:19 https://dx.doi.org/10.20517/rdodj.2023.14 Page 11 of 11

43. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ
2018;27:746-61. DOI PubMed
44. Valcárcel-Nazco C, García-Pérez L, Linertová R, et al. Cost-effectiveness methods of newborn screening assessment. Rev Esp Salud
Publica 2021;95:e202101009. Available from: https://www.mscbs.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_
cdrom/VOL95/C_ESPECIALES/RS95C_202101009.pdf [Last accessed on 9 Sep 2023]
45. Grosse SD, Thompson JD, Ding Y, Glass M. The use of economic evaluation to inform newborn screening policy decisions: the
washington state experience. Milbank Q 2016;94:366-91. DOI PubMed PMC
46. Forman J, Coyle F, Levy-Fisch J, Roberts P, Terry S, Legge M. Screening criteria: the need to deal with new developments and ethical
issues in newborn metabolic screening. J Community Genet 2013;4:59-67. DOI PubMed PMC
47. Nicholls SG, Southern KW. Informed choice for newborn blood spot screening in the United Kingdom: a survey of parental
perceptions. Pediatrics 2012;130:e1527-33. DOI PubMed
48. Wright SJ, Ulph F, Dharni N, Payne K. Eliciting preferences for information provision in newborn bloodspot screening programs.
Value Health 2017;20:651-61. DOI PubMed
49. Bailey DB Jr, Gehtland L. Newborn screening: evolving challenges in an era of rapid discovery. JAMA 2015;313:1511-2. DOI
PubMed PMC
50. Wasserstein MP, Andriola M, Arnold G, et al. Clinical outcomes of children with abnormal newborn screening results for Krabbe
disease in New York State. Genet Med 2016;18:1235-43. DOI
51. Howson CP, Cedergren B, Giugliani R, et al. Universal newborn screening: a roadmap for action. Mol Genet Metab 2018;124:177-83.
DOI
52. Pollitt RJ. International perspectives on newborn screening. J Inherit Metab Dis 2006;29:390-6. DOI PubMed
53. Fischer KE, Grosse SD, Rogowski WH. The role of health technology assessment in coverage decisions on newborn screening. Int J
Technol Assess Health Care 2011;27:313-21. DOI PubMed
54. Fischer KE, Rogowski WH. Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe. Int J
Environ Res Public Health 2014;11:5403-30. DOI PubMed PMC
55. Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of
data: a systematic review. Glob Health Action 2018;11:1447828. DOI PubMed PMC
56. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-
making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28. DOI PubMed
57. Marsh KD, Sculpher M, Caro JJ, Tervonen T. The use of MCDA in HTA: great potential, but more effort needed. Value Health
2018;21:394-7. DOI PubMed
58. Boy N, Mengler K, Thimm E, et al. Newborn screening: a disease-changing intervention for glutaric aciduria type 1. Ann Neurol
2018;83:970-9. DOI
59. Gramer G, Fang-Hoffmann J, Feyh P, et al. Newborn screening for vitamin B12 deficiency in Germany-strategies, results, and public
health implications. J Pediatr 2020;216:165-72.e4. DOI
60. Mütze U, Garbade SF, Gramer G, et al. Long-term outcomes of individuals with metabolic diseases identified through newborn
screening. Pediatrics 2020;146:e20200444. DOI
61. Hall K. 12th ISNS European regional meeting oral and poster abstracts. Int J Neonatal Screen 2021;7:71. DOI PubMed PMC
62. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the
ISPOR Real-World Data Task Force report. Value Health 2007;10:326-35. DOI PubMed